The currently available CSF GFAP data show a correlation between increased levels and Aβ and tau evidence of AD [115,300], and recent data on plasma GFAP showed increased concentrations in late and early onset AD patients compared with cognitively normal controls [301]. This evidence concerns the gene MAPT and Alzheimer disease.